Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mar ...

Welcome back. The Centers for Medicare and Medicaid Services just announcing lower negotiated prices on a slew of prescription drugs including the weight loss drugs ompic and WGO. Bertha Kums has the story for us.Bertha, >> hey David. Uh there are 15 drugs that were on the list for discounts in Medicare starting in 2027 and on average the Trump administration negotiated prices that are about 36% below the net price paid by Medicare back in 2024. Now that compares to about a 22% net discount for the first ro ...

We've got breaking news on drug pricing out of the CMS. Bertha Kums has got the details. Bertha, >> that's right, Melissa.The Centers for Medicare and Medicaid out with their inflation reduction act negotiated prices. These are the companies in the uh drugs that will be at these prices starting in 2027 in Medicare Part D. One of the biggest uh categories is diabetes of course, Goi, Rebelsis.In that uh cohort, the negotiated price is $274. at 71% below uh the list price but of course we know the MFN price is ...

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration’s plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk’s $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk’s history of exceeding investor expectations. Plus, U.S. airlines a ...

Mergers and Acquisitions - Metser is considered valuable due to the obesity market's potential, estimated to be upwards of $130 billion when combined with diabetes [1] - Pfizer's acquisition of Metser could establish them as a significant third player in the obesity market [2] - Novo needs the acquisition to bolster growth, given previous share declines and challenges [2] - A de-risked obesity asset like Metser is highly sought after, with potential for Pfizer's bid to surpass Novo Nordisk's; Pfizer has already received FTC clearance, allowing for a quick closing [7] Competitive Landscape - The obesity market is currently dominated by Lily and Novo [2] - Lily's oral GLP-1 pill launch next year will be a competitive product [3][4] - Meter provides Novo with a longer-acting GLP-1 option (once a month instead of once a week) and another option for amylin [5] - Novo aims to have multiple assets in the amylin space, including cagrilintide amylin and potentially the Metser asset [6] Drug Pricing and Market Access - A deal is expected where the lowest dose of weight loss drugs would be sold on Trump RX for $149 in exchange for Medicaid and Medicare coverage for obesity treatment [8] - The $149 price is meaningful as it addresses the missing piece of Medicare coverage for the obesity market [9] - The $299 price for Zepbound is a good deal, only $50 lower than Lily Direct's cash pay price, and higher doses are expected to be more expensive, resulting in a net win for Lily and Novo due to increased market access [9][10]

Prices for older drugs don't always drop. The latest Prognosis newsletter looks at why, and how Trump's deals are leaving out some costly treatments https://t.co/E3teuk6bx6 ...

Old drugs usually go way down in price, but not all of them. Here’s one that has gotten a lot more expensive over its decades on the market https://t.co/TEyGjtGwdh ...

Core Insights - CVS Health's pharmacy benefit manager, CVS Caremark, is delaying the addition of Gilead Sciences' new HIV prevention drug, Yeztugo, to its formularies due to pricing issues [2] Group 1 - CVS Caremark is prioritizing pricing concerns over the inclusion of new drugs in its formularies [2] - The decision to hold off on Yeztugo's addition reflects ongoing challenges in managing drug costs within the pharmacy benefit management sector [2]

It was only 2022 when you launched cost plus. It seems as though we've been having this conversation for a long time. >> Yeah.>> So much has happened in those three years. >> Where do you feel you are. Are you where you thought cost plus would be.>> Honestly, from the day we launched with 111 medications, we're so much further than I ever expected. Um the response has just been through the roof. And realize we don't spend a nickel on advertising or marketing.It's all word of mouth and we've had I mean we've ...

As an example, in London, you'd buy a certain drug for $130 and even less than that, I guess $88 as of account a month ago. And in New York, you pay $1,300 for the same thing. So now we're going to be paying uh instead of 1300, you'll be paying about $150. And they'll be paying $150, too.We're going to pay the same thing. Favored nations. It's beautiful. It's a beautiful thing.and we've been ripped off by the whole world for a long period of time. >> You mentioned a $1,300 drug at the top of this. Were you ...